


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-7.77%
-7.77%
+4.62%
+4.62%
-3.25%
-3.25%
OGN
Organon &
$7.62
Strengths

Earnings are forecast to grow

Investors confidence is positive
Risk Analysis

Downgraded on weak valued
Chart
$9.6 (-20.63%)
$9.44 (-19.28%)
$9.88 (-22.87%)
$14.88 (-48.79%)
OGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Downgraded on weak valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
OGN Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
OGN Street Sentiment is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is OGN current stock price?
What are OGN stock strengths?
What risks are associated with OGN stock?
When is OGN next earnings report?
What is OGN market cap and volume?
What is OGN's current Stock IQ?
Should I buy OGN stock right now?
Is OGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for OGN?
What does a 'Strong Sell' rating mean for OGN?
What factors influence OGN's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.77%
-7.77%
+4.62%
+4.62%
-3.25%
-3.25%
OGN
Organon &
Current Price
$7.62
Stock Insights
Strengths

Earnings are forecast to grow

Investors confidence is positive
Risk Analysis

Downgraded on weak valued

Chart
$9.6 (-20.63%)
$9.44 (-19.28%)
$9.88 (-22.87%)
$14.88 (-48.79%)
OGN Analysts Opinion
OGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Downgraded on weak valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
OGN Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
OGN Street Sentiment is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
OGN Latest Analysis
JP Morgan Maintains Organon (OGN) Underweight Recommendation. Fintel reports that on November 11 2025 JP Morgan maintained coverage of Organon (NYSE:OGN) with a Underweight recommendation. Analyst Price Forecast Suggests 46.94% Upside
Wed Nov 12, 2025
Morgan Stanley Maintains Organon (OGN) Equal-Weight Recommendation. Fintel reports that on November 11 2025 Morgan Stanley maintained coverage of Organon (NYSE:OGN) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 46.94% Upside
Wed Nov 12, 2025
Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends. We recently published 10 Stocks Beating the Market with Eye-Popping Gains. Organon &. Co. (NYSE:OGN) is one of the best-performing stocks on Monday. Organon extended its winning streak to a third straight day on Monday jumping 13.72 percent to close at $7.71 as investors snapped up shares ahead of the record date for its next [….]
Tue Nov 11, 2025
Organon Analysts Cut Their Forecasts Following Q3 Results. ) reported better-than-expected earnings for the third quarter on Monday.The company posted third-quarter adjusted earnings of $1.01 per share on Monday beating the consensus estimate of 94 cents. The global healthcare company reported quarterly sales of $1.602 billion beating the Wall Street estimate of $1.56 billion.Organon lowered its fiscal sales guidance from $6.275 billion-$6.375 billion to $6.20 billion-$6.25 billion below the con
Tue Nov 11, 2025
Organon & Co. (NYSE:OGN) Q3 2025 Earnings Call Transcript. Organon &. Co. (NYSE:OGN) Q3 2025 Earnings Call Transcript November 10 2025 Organon &. Co. misses on earnings expectations. Reported EPS is $0.00061 EPS expectations were $0.93. Operator: Hello and welcome to the Organon Third Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak [….]
Tue Nov 11, 2025
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates. Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended September 2025 it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Mon Nov 10, 2025
Organon cuts outlook despite Q3 beat amid JADA divestment.
Mon Nov 10, 2025
Organon declares $0.02 dividend.
Mon Nov 10, 2025
Organon lowers 2025 revenue guidance to $6.2B–$6.25B amid United States Nexplanon headwinds and Jada divestiture.
Mon Nov 10, 2025
Organon (OGN) Q3 Earnings and Revenues Beat Estimates. Organon (OGN) delivered earnings and revenue surprises of 8.60% and 2.02% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Mon Nov 10, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.